An open-label extension study of lurasidone in patients with schizophrenia previously randomized to lurasidone or risperidone

被引：0
|
作者：
Mattingly, G. [1 ]
Tocco, M. [2 ]
Cucchiaro, J. [3 ]
Xu, J. [3 ]
Pikalov, A. [3 ]
Loebel, A. [3 ]
机构：
[1] St Charles Psychiat Associates, St Charles, MO USA
[2] Sunov Pharmaceut Inc, Marlborough, MA USA
[3] Sunov Pharmaceut Inc, Ft Lee, VA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
D O I：
10.1016/S0924-977X(14)70895-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.062
引用
收藏
页码：S559 / S559
页数：1
相关论文
共 50 条
  • [1] An open-label extension study of lurasidone safety and efficacy in patients with schizophrenia previously randomized to lurasidone or risperidone
    Mattingly, G.
    Tocco, M.
    Cucchiaro, J.
    Xu, J.
    Loebel, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 147 - 147
  • [2] Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Takai, Kentaro
    Higuchi, Teruhiko
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2683 - 2695
  • [3] Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study
    Stahl, Stephen M.
    Cucchiaro, Josephine
    Simonelli, Doreen
    Hsu, Jay
    Pikalov, Andrei
    Loebel, Antony
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (05) : 507 - 515
  • [4] Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
    Miura, Itaru
    Watabe, Kei
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Maruyama, Hidenori
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 2627 - 2637
  • [5] Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study
    Correll, C. U.
    Arango, C.
    Tocco, M.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1099 - S1099
  • [6] Effectiveness of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study
    Tocco, M.
    Arango, C.
    Correll, C. U.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1100 - S1101
  • [7] Efficacy and safety of lurasidone in adolescents with schizophrenia: analysis of a 2-year, open-label extension study
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Ling, D.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S275 - S276
  • [8] Efficacy and safety of lurasidone in adolescents with schizophrenia: Results of a 2-year, open-label extension study
    Goldman, R.
    Correll, C.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S88 - S89
  • [9] EFFECTIVENESS AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: ANALYSIS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C. U.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2021, 55 (1_SUPPL): : 103 - 104
  • [10] Effect of lurasidone on cognition in adolescents with schizophrenia: analysis of a 2-year open-label extension study
    Harvey, P. D.
    Goldman, R.
    Tocco, M.
    Deng, L.
    Cucchiaro, J.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S284 - S285
12345